ARTHEx Biotech to Present Preclinical Data on ATX-01 for Myotonic Dystrophy Type 1 (DM1) at TIDES USA 2023 Meeting

VALENCIA, Spain, May 9, 2023 /PRNewswire/ — ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced today a presentation at the TIDES USA Oligonucleotide & Peptide Therapeutics annual meeting…